Status:

NOT_YET_RECRUITING

Hypoproteic Diet in Acromegaly

Lead Sponsor:

Azienda Ospedaliero Universitaria Maggiore della Carita

Conditions:

Acromegaly

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

Since protein and AAs are master regulator of GH and IGF-I secretion, we hypothesized that a low protein diet could reduce GH and IGF-I levels in acromegalic patients in addition to conventional thera...

Detailed Description

Nutrients are crucial modifiers of the GH/IGF-I axis. In particular, a close cross-talk between proteins and amino acids (AAs) and GH/IGF-I secretion exists. Both AAs and proteins affect GH secretion...

Eligibility Criteria

Inclusion

  • Age 18/65
  • Diagnosis of Acromegaly
  • In therapy with somatostatin analogues

Exclusion

  • pregnancy or lactation
  • alchool or drugs abuse
  • cancer
  • Hematological diseases

Key Trial Info

Start Date :

September 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2026

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT05298891

Start Date

September 1 2024

End Date

March 1 2026

Last Update

September 28 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

: Italy Pediatric Endocrine Service of AOU Maggiore della Carità of Novara; SCDU of Pediatrics, Department of Health Sciences, University of Eastern Piedmont

Novara, Italy, 28100